Product Description

Gelatin is a heterogenous mixture of water-soluble proteins with high average molecular masses. Gelatin proteins are derived by denaturing collagen-rich tissue in water [1]. The mechanical properties of gelatin, such as gel stiffness and compressibility, are related to the average molecular weight of the gelatin proteins and characterized by its Bloom number [2]. Humabiologics^® offers the first and only human gelatin in the market derived from bone at Bloom numbers between 90-300 g to meet the needs of translational research and regenerative therapies. Bloom is proportional to the average gelatin molecular mass.

Biomedical applications of human gelatin include coating tissue culture surfaces with a thin layer of protein to improve cell attachment for a variety of cell types [3]. Due to the excellent biocompatibility of gelatin, it has been used to generate 3D scaffolds and hydrogels for tissue engineering applications [4], and as a delivery material to control the release of bioactive molecules [5]. In the pharmaceutical industry, gelatin is used as an encapsulating agent and binder for tablet production [6]. Gelatin can be combined with other human-derived biomaterials- such as Collagen Type I from human skin (HumaDerm^TM offered by Humabiologics^®) – to make completely human-derived tissue engineered composites [7].

Huma OsteoGelatin^TM, Medium Bloom is ideal for coating tissue culture surfaces with a thin layer of gelatin to support rapid cell attachment and growth or for hydrogel application. The optimal gelatin concentration used may vary depending on cell type or experiment and must be titrated for best results.

Tissue Source

Huma OsteoGelatin^TM is extracted and purified from human bone sourced strictly from American Association of Tissue Banks (AATB) accredited and FDA registered tissue banks and organ procurement organizations (OPOs). Humabiologics^® strives to meet research needs by providing high quality biomaterials obtained from tissue partners who comply with requirements for transplantable human tissues under 21 CFR 1271 of the Food and Drug Administration (FDA).

Precautions and Disclaimer

Huma OsteoGelatin^TM is obtained from human tissue that has been tested and found negative for a minimum of HIV-1 and -2, hepatitis B, and hepatitis C, as well as other infectious agents. Please review the Safety Data Sheet (SDS) for information regarding hazards and safe handling practices. Huma OsteoGelatin^TM is for research use only and is not intended for human use, diagnosis, screening, household, food or other uses.

Storage Conditions/Reconstitution

This product can be stored in airtight containers at ambient temperature (15-30 °C) upon receipt and prior to solubilization. Research grade products have a shelf life of 6 months upon receipt.

Huma OsteoGelatin^TM can be reconstituted in 37 °C water or PBS to the desired concentration with agitation/vortexing for several minutes. Dissolving time depends on the gelatin concentration but usually takes a few minutes for low concentration. Centrifugation might be used to remove undissolved particulate. After reconstitution, solution should be used immediately or stored at 2-10 °C. Solubilized gelatin can be sterilized by filtration through a 0.22 µm membrane.

References

1. Gelatin Manufacturers Institute of America Inc, Gelatin Handbook. 2012: 51 W 52nd St, New York, New York 10019, US.
2. Gelatin Manufacturers Institute of America Inc, Standard Methods for the Sampling and Testing of Gelatins. 1986: 51 W 52nd St, New York, New York 10019, US.
3. Davidenko, N., et al., Evaluation of cell binding to collagen and gelatin: a study of the effect of 2D and 3D architecture and surface chemistry. J Mater Sci Mater Med, 2016. 27(10): p. 148.
4. Kang, H.W., Y. Tabata, and Y. Ikada, Fabrication of porous gelatin scaffolds for tissue engineering. Biomaterials, 1999. 20(14): p. 1339-44.
5. Dong, Z., Q. Wang, and Y. Du, Alginate/gelatin blend films and their properties for drug controlled release. Journal of Membrane Science, 2006. 280(1): p. 37-44.
6. Corveleyn, S. and J.P. Remon, Formulation and production of rapidly disintegrating tablets by lyophilisation using hydrochlorothiazide as a model drug. International Journal of Pharmaceutics, 1997. 152(2): p. 215-225.
7. Gautam, S., et al., Surface modification of nanofibrous polycaprolactone/gelatin composite scaffold by collagen type I grafting for skin tissue engineering. Materials Science and Engineering: C, 2014. 34: p. 402-409.